Eusol was established in 2005 and has been collaborating with Taiwanese Neurosurgery and Rehabilitation medical experts to evaluate the efficacy of ES135 (rhFGF1) in patients with traumatic spinal cord and peripheral nerve injuries. Over the years, ES135 has been evaluated by a series of clinical studies conducted at VGH Taipei, and significant and dramatic improvements were observed in some cases. These were filmed as a documentary and presented in a National Geography special report. In addition, Taiwan FDA granted three medical centers Expanded Access (Compassionate Use) program for the use of Eusol Biotech's ES135 to treat more than 100 patients with acute or chronic spinal cord injuries.

Currently, Eusol is vigorously expanding its therapeutic areas and looking for drugs in niche markets to meet patients with special needs.